Expression levels of serine/glycine metabolism-related proteins in triple negative breast cancer tissues

Songmi Noh, Do Hee Kim, Woo Hee Jung, JaSeung Koo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

To evaluate the expression levels of serine/glycine metabolism-related proteins (PHGDH, PSAT, PSPH, SHMT, and GLDC) in six different subtypes of triple negative breast cancer (TNBC) patients and gain insight into their implications. Formalin-fixed, paraffin-embedded tissues from 129 TNBC patients were assembled into tissue microarrays. Immunohistochemical staining was performed for serine/glycine metabolism-related proteins (PHGDH, PSAT, PSPH, SHMT, and GLDC) and surrogate immunohistochemical markers (CK5/6, EGFR, claudin 3, claudin 4, claudin 7, E-cadherin, STAT1, interleukin-8 [IL-8], AR, and GGT-1) for identifying the molecular subtype of TNBC. TNBC subtype classifications included the following: basal-like (CK5/6-positive and/or EGFR-positive), molecular apocrine (AR-positive and/or GGT-1-positive), claudin-low (claudin 3-, claudin 4-, claudin 7-negative and/or E-cadherin-negative), immune-related (IL-8-negative and stromal STAT1-positive), mixed (features from two or more of the four subtypes), and null (no features from any of the four subtypes). Tissues from basal marker-positive patients showed increased expression levels of tumoral PHGDH compared with those from basal marker-negative patients (p=0.029); lack of stromal SHMT1 expression was significantly correlated with T stage (p=0.016). Multivariate Cox analysis revealed that a lack of stromal SHMT1 expression was an independent prognostic factor for predicting a shorter disease-free survival period (hazard ratio 4.002, 95% confidence interval [CI] 1.077-14.83, p=0.038); furthermore, a lack of tumoral PHGDH expression was predictive of a shorter overall survival rate (hazard ratio 3.053, 95% CI 1.002-9.305, p=0.050). In conclusion, the most abundantly expressed serine/glycine metabolism-related protein in basal-like TNBC tissues was tumoral PHGDH, and expression levels of stromal SHMT1 and tumoral PHGDH were inversely correlated with clinical prognostic factors. Also, this study is the first to assess serine/glycine relationships at the protein level in regards to clinical outcomes.

Original languageEnglish
Pages (from-to)4457-4468
Number of pages12
JournalTumor Biology
Volume35
Issue number5
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Triple Negative Breast Neoplasms
Glycine
Serine
phosphoserine aminotransferase
Claudin-3
Claudin-4
Cadherins
Proteins
Interleukin-8
Claudin-1
Confidence Intervals
Paraffin
Formaldehyde
Disease-Free Survival
Multivariate Analysis
Survival Rate
Biomarkers
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Cancer Research

Cite this

Noh, Songmi ; Kim, Do Hee ; Jung, Woo Hee ; Koo, JaSeung. / Expression levels of serine/glycine metabolism-related proteins in triple negative breast cancer tissues. In: Tumor Biology. 2014 ; Vol. 35, No. 5. pp. 4457-4468.
@article{533d259b3fc74f1980bb0b37c4e20dd7,
title = "Expression levels of serine/glycine metabolism-related proteins in triple negative breast cancer tissues",
abstract = "To evaluate the expression levels of serine/glycine metabolism-related proteins (PHGDH, PSAT, PSPH, SHMT, and GLDC) in six different subtypes of triple negative breast cancer (TNBC) patients and gain insight into their implications. Formalin-fixed, paraffin-embedded tissues from 129 TNBC patients were assembled into tissue microarrays. Immunohistochemical staining was performed for serine/glycine metabolism-related proteins (PHGDH, PSAT, PSPH, SHMT, and GLDC) and surrogate immunohistochemical markers (CK5/6, EGFR, claudin 3, claudin 4, claudin 7, E-cadherin, STAT1, interleukin-8 [IL-8], AR, and GGT-1) for identifying the molecular subtype of TNBC. TNBC subtype classifications included the following: basal-like (CK5/6-positive and/or EGFR-positive), molecular apocrine (AR-positive and/or GGT-1-positive), claudin-low (claudin 3-, claudin 4-, claudin 7-negative and/or E-cadherin-negative), immune-related (IL-8-negative and stromal STAT1-positive), mixed (features from two or more of the four subtypes), and null (no features from any of the four subtypes). Tissues from basal marker-positive patients showed increased expression levels of tumoral PHGDH compared with those from basal marker-negative patients (p=0.029); lack of stromal SHMT1 expression was significantly correlated with T stage (p=0.016). Multivariate Cox analysis revealed that a lack of stromal SHMT1 expression was an independent prognostic factor for predicting a shorter disease-free survival period (hazard ratio 4.002, 95{\%} confidence interval [CI] 1.077-14.83, p=0.038); furthermore, a lack of tumoral PHGDH expression was predictive of a shorter overall survival rate (hazard ratio 3.053, 95{\%} CI 1.002-9.305, p=0.050). In conclusion, the most abundantly expressed serine/glycine metabolism-related protein in basal-like TNBC tissues was tumoral PHGDH, and expression levels of stromal SHMT1 and tumoral PHGDH were inversely correlated with clinical prognostic factors. Also, this study is the first to assess serine/glycine relationships at the protein level in regards to clinical outcomes.",
author = "Songmi Noh and Kim, {Do Hee} and Jung, {Woo Hee} and JaSeung Koo",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s13277-013-1588-z",
language = "English",
volume = "35",
pages = "4457--4468",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "5",

}

Expression levels of serine/glycine metabolism-related proteins in triple negative breast cancer tissues. / Noh, Songmi; Kim, Do Hee; Jung, Woo Hee; Koo, JaSeung.

In: Tumor Biology, Vol. 35, No. 5, 01.01.2014, p. 4457-4468.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression levels of serine/glycine metabolism-related proteins in triple negative breast cancer tissues

AU - Noh, Songmi

AU - Kim, Do Hee

AU - Jung, Woo Hee

AU - Koo, JaSeung

PY - 2014/1/1

Y1 - 2014/1/1

N2 - To evaluate the expression levels of serine/glycine metabolism-related proteins (PHGDH, PSAT, PSPH, SHMT, and GLDC) in six different subtypes of triple negative breast cancer (TNBC) patients and gain insight into their implications. Formalin-fixed, paraffin-embedded tissues from 129 TNBC patients were assembled into tissue microarrays. Immunohistochemical staining was performed for serine/glycine metabolism-related proteins (PHGDH, PSAT, PSPH, SHMT, and GLDC) and surrogate immunohistochemical markers (CK5/6, EGFR, claudin 3, claudin 4, claudin 7, E-cadherin, STAT1, interleukin-8 [IL-8], AR, and GGT-1) for identifying the molecular subtype of TNBC. TNBC subtype classifications included the following: basal-like (CK5/6-positive and/or EGFR-positive), molecular apocrine (AR-positive and/or GGT-1-positive), claudin-low (claudin 3-, claudin 4-, claudin 7-negative and/or E-cadherin-negative), immune-related (IL-8-negative and stromal STAT1-positive), mixed (features from two or more of the four subtypes), and null (no features from any of the four subtypes). Tissues from basal marker-positive patients showed increased expression levels of tumoral PHGDH compared with those from basal marker-negative patients (p=0.029); lack of stromal SHMT1 expression was significantly correlated with T stage (p=0.016). Multivariate Cox analysis revealed that a lack of stromal SHMT1 expression was an independent prognostic factor for predicting a shorter disease-free survival period (hazard ratio 4.002, 95% confidence interval [CI] 1.077-14.83, p=0.038); furthermore, a lack of tumoral PHGDH expression was predictive of a shorter overall survival rate (hazard ratio 3.053, 95% CI 1.002-9.305, p=0.050). In conclusion, the most abundantly expressed serine/glycine metabolism-related protein in basal-like TNBC tissues was tumoral PHGDH, and expression levels of stromal SHMT1 and tumoral PHGDH were inversely correlated with clinical prognostic factors. Also, this study is the first to assess serine/glycine relationships at the protein level in regards to clinical outcomes.

AB - To evaluate the expression levels of serine/glycine metabolism-related proteins (PHGDH, PSAT, PSPH, SHMT, and GLDC) in six different subtypes of triple negative breast cancer (TNBC) patients and gain insight into their implications. Formalin-fixed, paraffin-embedded tissues from 129 TNBC patients were assembled into tissue microarrays. Immunohistochemical staining was performed for serine/glycine metabolism-related proteins (PHGDH, PSAT, PSPH, SHMT, and GLDC) and surrogate immunohistochemical markers (CK5/6, EGFR, claudin 3, claudin 4, claudin 7, E-cadherin, STAT1, interleukin-8 [IL-8], AR, and GGT-1) for identifying the molecular subtype of TNBC. TNBC subtype classifications included the following: basal-like (CK5/6-positive and/or EGFR-positive), molecular apocrine (AR-positive and/or GGT-1-positive), claudin-low (claudin 3-, claudin 4-, claudin 7-negative and/or E-cadherin-negative), immune-related (IL-8-negative and stromal STAT1-positive), mixed (features from two or more of the four subtypes), and null (no features from any of the four subtypes). Tissues from basal marker-positive patients showed increased expression levels of tumoral PHGDH compared with those from basal marker-negative patients (p=0.029); lack of stromal SHMT1 expression was significantly correlated with T stage (p=0.016). Multivariate Cox analysis revealed that a lack of stromal SHMT1 expression was an independent prognostic factor for predicting a shorter disease-free survival period (hazard ratio 4.002, 95% confidence interval [CI] 1.077-14.83, p=0.038); furthermore, a lack of tumoral PHGDH expression was predictive of a shorter overall survival rate (hazard ratio 3.053, 95% CI 1.002-9.305, p=0.050). In conclusion, the most abundantly expressed serine/glycine metabolism-related protein in basal-like TNBC tissues was tumoral PHGDH, and expression levels of stromal SHMT1 and tumoral PHGDH were inversely correlated with clinical prognostic factors. Also, this study is the first to assess serine/glycine relationships at the protein level in regards to clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84902953615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902953615&partnerID=8YFLogxK

U2 - 10.1007/s13277-013-1588-z

DO - 10.1007/s13277-013-1588-z

M3 - Article

C2 - 24390667

AN - SCOPUS:84902953615

VL - 35

SP - 4457

EP - 4468

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 5

ER -